Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 8/20 | 0.38 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4737549 | 0.76 | ACE (0.41) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL28789104 | 0.76 | ACE (0.41) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL16598691 | 0.73 | ACE (0.38) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL28453300 | 0.73 | ACE (0.35) | ACE | |
| SCHEMBL25166719 | 0.72 | HTT (0.38) | ACEREN | |
| SCHEMBL10903234 | 0.72 | KDM4E (0.42) | ACE | |
| SCHEMBL23118022 | 0.72 | CA2 (0.39) | ACE | |
| SCHEMBL22175770 | 0.72 | ACE (0.41) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL23118025 | 0.72 | CA2 (0.39) | ACE | |
| SCHEMBL2678393 | 0.72 | ACE (0.41) | ACERENLMNACYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118200-A1 | Proline bis-amide orexin receptor antagonists | MERCK SHARP & DOHME CORP. | 2009-05-07 | — | — | US | disclosed |
| EP-1888563-A1 | PROLINE BIS-AMIDE OREXIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006127550-A1 | PROLINE BIS-AMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118200-A1 | Proline bis-amide orexin receptor antagonists | HCRTR1, HCRTR2, NPSR1 | ACE 772/4885REN 362/4885LMNA 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.